Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Factor Xa"" wg kryterium: Temat


Tytuł :
Activated prothrombin complex concentrate for reversal of oral factor Xa inhibitors at a level 1 trauma center.
Autorzy :
Bobby L; Department of Pharmacy, Allegheny General Hospital, 320 E North Ave, Pittsburgh, PA 15212, United States of America. Electronic address: .
Westlake E; Department of Pharmacy, Allegheny General Hospital, 320 E North Ave, Pittsburgh, PA 15212, United States of America.
Esplin N; Department of Neurosurgery, Allegheny General Hospital, 320 E North Ave, Pittsburgh, PA 15212, United States of America.
Young S; Department of Pharmacy, Allegheny General Hospital, 320 E North Ave, Pittsburgh, PA 15212, United States of America.
Pokaż więcej
Źródło :
Thrombosis research [Thromb Res] 2021 Oct; Vol. 206, pp. 33-35. Date of Electronic Publication: 2021 Aug 10.
Typ publikacji :
Journal Article
MeSH Terms :
Factor Xa Inhibitors*/therapeutic use
Trauma Centers*
Blood Coagulation Factors ; Factor VIIa ; Factor Xa ; Humans ; Recombinant Proteins ; Rivaroxaban
Czasopismo naukowe
Tytuł :
Structure-function of anticoagulant TIX-5, the inhibitor of factor Xa-mediated FV activation.
Autorzy :
Maag A; Amsterdam UMC, University of Amsterdam, Center for Experimental and Molecular Medicine, Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands.; Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands.
Sharma P; Amsterdam UMC, University of Amsterdam, Center for Experimental and Molecular Medicine, Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands.
Schuijt TJ; Hospital Gelderse Vallei Ede, Clinical Chemistry and Hematology Laboratory, Ede, The Netherlands.
Kopatz WF; Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Kruijswijk D; Amsterdam UMC, University of Amsterdam, Center for Experimental and Molecular Medicine, Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands.
Marquart JA; Department of Molecular and Cellular Hemostasis, Sanquin Research, Amsterdam, The Netherlands.
van der Poll T; Amsterdam UMC, University of Amsterdam, Center for Experimental and Molecular Medicine, Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands.
Hackeng TM; Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM) Maastricht University, Maastricht, The Netherlands.
Nicolaes GAF; Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM) Maastricht University, Maastricht, The Netherlands.
Meijers JCM; Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.; Department of Molecular and Cellular Hemostasis, Sanquin Research, Amsterdam, The Netherlands.
Bos MHA; Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands.
van 't Veer C; Amsterdam UMC, University of Amsterdam, Center for Experimental and Molecular Medicine, Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2021 Jul; Vol. 19 (7), pp. 1697-1708. Date of Electronic Publication: 2021 May 01.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anticoagulants*
Factor Xa Inhibitors*/pharmacology
Blood Coagulation ; Factor V ; Factor Va ; Factor Xa ; Humans ; Prothrombin ; Thrombin ; Thromboplastin
Czasopismo naukowe
Tytuł :
Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage.
Autorzy :
Ammar AA; Department of Pharmacy, Yale New Haven Hospital, 55 Park Street, Lower Level, New Haven, CT, 06510, USA.
Ammar MA; Department of Pharmacy, Yale New Haven Hospital, 55 Park Street, Lower Level, New Haven, CT, 06510, USA.
Owusu KA; Department of Pharmacy, Yale New Haven Hospital, 55 Park Street, Lower Level, New Haven, CT, 06510, USA.; Clinical Redesign, Yale New Haven Health, New Haven, CT, USA.
Brown SC; Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale School of Medicine, 15 York Street, LLCI 1004D, Box 208018, New Haven, CT, 06520, USA.
Kaddouh F; Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale School of Medicine, 15 York Street, LLCI 1004D, Box 208018, New Haven, CT, 06520, USA.
Elsamadicy AA; Departments of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.
Acosta JN; Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale School of Medicine, 15 York Street, LLCI 1004D, Box 208018, New Haven, CT, 06520, USA.
Falcone GJ; Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale School of Medicine, 15 York Street, LLCI 1004D, Box 208018, New Haven, CT, 06520, USA. .
Pokaż więcej
Źródło :
Neurocritical care [Neurocrit Care] 2021 Aug; Vol. 35 (1), pp. 255-261. Date of Electronic Publication: 2021 Jan 06.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Blood Coagulation Factors*/pharmacology
Factor Xa Inhibitors*/adverse effects
Adult ; Anticoagulants/adverse effects ; Factor Xa ; Female ; Humans ; Infant, Newborn ; Intracranial Hemorrhages/chemically induced ; Intracranial Hemorrhages/drug therapy ; Male ; Recombinant Proteins ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Peak plasma rivaroxaban levels in patients weighing 120 kg or greater.
Autorzy :
Abdulrehman J; Division of Hematology, Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada. Electronic address: .
Selby R; Department of Laboratory Medicine and Pathobiology & Medicine, University Health Network and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
Joundi RA; Department of Clinical Neurosciences, University of Calgary, AB, Canada.
Yeo E; Division of Hematology, Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.
Pokaż więcej
Źródło :
Thrombosis research [Thromb Res] 2021 May; Vol. 201, pp. 15-17. Date of Electronic Publication: 2021 Feb 18.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Factor Xa Inhibitors*/therapeutic use
Rivaroxaban*/therapeutic use
Factor Xa ; Humans
Raport
Tytuł :
Use and outcomes of prothrombin complex concentrate for factor Xa inhibitor-associated bleeding.
Autorzy :
Frank AK; Department of Medicine, University of California, San Francisco, United States of America. Electronic address: .
Ganesan P; Department of Medicine, University of California, San Francisco, United States of America.
Thompson A; Department of Clinical Pharmacy, University of California, San Francisco, United States of America.
Fang MC; Division of Hospital Medicine, Department of Medicine, University of California, San Francisco, United States of America.
Pokaż więcej
Źródło :
Thrombosis research [Thromb Res] 2021 Feb; Vol. 198, pp. 132-134. Date of Electronic Publication: 2020 Dec 08.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Blood Coagulation Factors*
Factor Xa Inhibitors*/adverse effects
Factor IX ; Factor Xa ; Hemorrhage/chemically induced ; Humans ; Prothrombin
Czasopismo naukowe
Tytuł :
Elevated anti-human factor Xa activity in rabbit and rodent plasma: Implications for preclinical assessment of human factor X in animal models of hemostasis.
Autorzy :
Verhoef D; Department of Internal Medicine, Division of Thrombosis and Hemostasis, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands; VarmX B.V., Leiden, the Netherlands.
Tjalma AVR; Department of Internal Medicine, Division of Thrombosis and Hemostasis, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Cheung KL; Department of Internal Medicine, Division of Thrombosis and Hemostasis, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Reitsma PH; Department of Internal Medicine, Division of Thrombosis and Hemostasis, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands; VarmX B.V., Leiden, the Netherlands.
Bos MHA; Department of Internal Medicine, Division of Thrombosis and Hemostasis, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: .
Pokaż więcej
Źródło :
Thrombosis research [Thromb Res] 2021 Feb; Vol. 198, pp. 154-162. Date of Electronic Publication: 2020 Nov 28.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Factor X*
Factor Xa*
Animals ; Blood Coagulation Tests ; Factor Xa Inhibitors ; Hemostasis ; Humans ; Mice ; Models, Animal ; Partial Thromboplastin Time ; Prothrombin Time ; Rabbits ; Rats ; Rodentia ; Swine
Czasopismo naukowe
Tytuł :
The AAST prospective observational multicenter study of the initial experience with reversal of direct oral anticoagulants in trauma patients.
Autorzy :
Emigh B; Dell Seton Medical Center at the University of Texas at Austin, TX, United States. Electronic address: .
Kobayashi L; University of California, San Diego, United States.
Kopp M; Weill Cornell Physicians, United States.
Daley M; Dell Seton Medical Center, United States.
Teal L; Dell Seton Medical Center, United States.
Haan J; University of Kansas School of Medicine Wichita, United States.
Burlew CC; University of Colorado Denver - Anschutz Medical Campus, United States.
Nirula R; University of Utah Hospital, United States.
Moore F; Chandler Regional Medical Center, United States.
Burruss S; Loma Linda University Medical Center, United States.
Kaminski S; Santa Barbara Cottage Hospital, United States.
Dunn J; University of Colorado Hospital, United States.
Carrick M; Medical Center of Plano, United States.
Schroeppel T; UCHealth Memorial Hospital Central, United States.
Thurston B; Spartanburg Regional Medical Center, United States.
Quick J; University of Missouri Health Care, United States.
Bosarge P; University of Birmingham College of Medical and Dental Sciences, United States.
Brown CV; Dell Seton Medical Center, United States.
Pokaż więcej
Źródło :
American journal of surgery [Am J Surg] 2021 Aug; Vol. 222 (2), pp. 264-269. Date of Electronic Publication: 2021 Jan 06.
Typ publikacji :
Journal Article; Multicenter Study; Observational Study
MeSH Terms :
Coagulants/*therapeutic use
Factor Xa Inhibitors/*administration & dosage
Hemorrhage/*prevention & control
Wounds and Injuries/*therapy
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/therapeutic use ; Blood Coagulation Factors/therapeutic use ; Factor Xa/therapeutic use ; Female ; Humans ; Injury Severity Score ; Male ; Prospective Studies ; Recombinant Proteins/therapeutic use ; Survival Rate ; Trauma Centers ; Wounds and Injuries/complications ; Wounds and Injuries/mortality
Czasopismo naukowe
Tytuł :
The incidence of thrombotic events with idarucizumab and andexanet alfa: A systematic review and meta-analysis.
Autorzy :
Rodrigues AO; Faculdade de Medicina, Universidade de Lisboa, Portugal.
David C; Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Portugal; Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Portugal; Centro Cardiovascular da Universidade de Lisboa - CCUL, CAML, Faculdade de Medicina, Universidade de Lisboa, Portugal; Serviço de Cardiologia, Hospital Universitário de Santa Maria - CHULN, Portugal.
Ferreira JJ; Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Portugal; Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Portugal.
Pinto FJ; Centro Cardiovascular da Universidade de Lisboa - CCUL, CAML, Faculdade de Medicina, Universidade de Lisboa, Portugal; Serviço de Cardiologia, Hospital Universitário de Santa Maria - CHULN, Portugal.
Costa J; Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Portugal; Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Portugal.
Caldeira D; Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Portugal; Centro Cardiovascular da Universidade de Lisboa - CCUL, CAML, Faculdade de Medicina, Universidade de Lisboa, Portugal; Serviço de Cardiologia, Hospital Universitário de Santa Maria - CHULN, Portugal. Electronic address: .
Pokaż więcej
Źródło :
Thrombosis research [Thromb Res] 2020 Dec; Vol. 196, pp. 291-296. Date of Electronic Publication: 2020 Sep 03.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Anticoagulants*/adverse effects
Factor Xa*
Administration, Oral ; Antibodies, Monoclonal, Humanized ; Antidotes/adverse effects ; Factor Xa Inhibitors ; Humans ; Incidence ; Prospective Studies ; Recombinant Proteins ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis.
Autorzy :
Nederpelt CJ; Department of Trauma Surgery, Leiden University Medical Center, Leiden, The Netherlands.; Division of Trauma, Emergency Surgery, and Surgical Critical Care, Department of Surgery, Massachusetts General Hospital, Boston, MA.
Naar L; Division of Trauma, Emergency Surgery, and Surgical Critical Care, Department of Surgery, Massachusetts General Hospital, Boston, MA.
Krijnen P; Department of Trauma Surgery, Leiden University Medical Center, Leiden, The Netherlands.
le Cessie S; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
Kaafarani HMA; Division of Trauma, Emergency Surgery, and Surgical Critical Care, Department of Surgery, Massachusetts General Hospital, Boston, MA.
Huisman MV; Department of Thrombosis and Haemostasis, Leiden University Medical Center, Leiden, The Netherlands.
Velmahos GC; Division of Trauma, Emergency Surgery, and Surgical Critical Care, Department of Surgery, Massachusetts General Hospital, Boston, MA.
Schipper IB; Department of Trauma Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Pokaż więcej
Źródło :
Critical care medicine [Crit Care Med] 2021 Oct 01; Vol. 49 (10), pp. e1025-e1036.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Factor Xa/*pharmacology
Factor Xa Inhibitors/*adverse effects
Hemorrhage/*drug therapy
Prothrombin/*pharmacology
Recombinant Proteins/*pharmacology
Coagulants/administration & dosage ; Coagulants/pharmacology ; Factor Xa/administration & dosage ; Factor Xa Inhibitors/pharmacology ; Humans ; Prothrombin/administration & dosage ; Recombinant Proteins/administration & dosage
Czasopismo naukowe
Tytuł :
A Systemwide Approach for Navigating the Dilemma of Oral Factor Xa Inhibitor Interference With Unfractionated Heparin Anti-Factor Xa Concentrations.
Autorzy :
Levito MN; UPMC Presbyterian-Shadyside, Pittsburgh, PA, USA.
Coons JC; UPMC Presbyterian-Shadyside, Pittsburgh, PA, USA.; University of Pittsburgh-School of Pharmacy, Pittsburgh, PA, USA.
Verrico MM; UPMC Presbyterian-Shadyside, Pittsburgh, PA, USA.
Szymkowiak A; UPMC Presbyterian-Shadyside, Pittsburgh, PA, USA.
Legler B; UPMC Presbyterian-Shadyside, Pittsburgh, PA, USA.; Duquesne University, Pittsburgh, PA, USA.
Dueweke EJ; UPMC Presbyterian-Shadyside, Pittsburgh, PA, USA.
Kane-Gill SL; UPMC Presbyterian-Shadyside, Pittsburgh, PA, USA.; University of Pittsburgh-School of Pharmacy, Pittsburgh, PA, USA.
Pokaż więcej
Źródło :
The Annals of pharmacotherapy [Ann Pharmacother] 2021 May; Vol. 55 (5), pp. 618-623. Date of Electronic Publication: 2020 Sep 04.
Typ publikacji :
Journal Article
MeSH Terms :
Anticoagulants/*administration & dosage
Drug Monitoring/*methods
Factor Xa Inhibitors/*administration & dosage
Heparin/*administration & dosage
Administration, Intravenous ; Administration, Oral ; Aged ; Aged, 80 and over ; Anticoagulants/blood ; Factor Xa/metabolism ; Factor Xa Inhibitors/blood ; Female ; Fibrinolytic Agents/administration & dosage ; Fibrinolytic Agents/blood ; Heparin/blood ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Thrombosis/blood ; Thrombosis/drug therapy
Czasopismo naukowe
Tytuł :
Anticoagulation with direct factor Xa inhibitors in transplant recipients: Results from the DRESDEN NOAC REGISTRY (NCT01588119).
Autorzy :
Beyer-Westendorf J; Department of Medicine I, Division of Hematology, Hemostaseology and Coagulation, University Hospital 'Carl Gustav Carus' Dresden, Technical University, Fetscherstrasse 74, D-01307 Dresden, Germany; Kings Thrombosis Service, Department of Hematology, Kings College London, UK. Electronic address: .
Marten S; Department of Medicine I, Division of Hematology, Hemostaseology and Coagulation, University Hospital 'Carl Gustav Carus' Dresden, Technical University, Fetscherstrasse 74, D-01307 Dresden, Germany.
Naue C; Department of Medicine I, Division of Hematology, Hemostaseology and Coagulation, University Hospital 'Carl Gustav Carus' Dresden, Technical University, Fetscherstrasse 74, D-01307 Dresden, Germany.
Tittl L; Department of Medicine I, Division of Hematology, Hemostaseology and Coagulation, University Hospital 'Carl Gustav Carus' Dresden, Technical University, Fetscherstrasse 74, D-01307 Dresden, Germany.
Sockel K; Department of Medicine I, Division of Hematology, Hemostaseology and Coagulation, University Hospital 'Carl Gustav Carus' Dresden, Technical University, Fetscherstrasse 74, D-01307 Dresden, Germany.
Middecke JM; Department of Medicine I, Division of Hematology, Hemostaseology and Coagulation, University Hospital 'Carl Gustav Carus' Dresden, Technical University, Fetscherstrasse 74, D-01307 Dresden, Germany.
Bornhäuser M; Department of Medicine I, Division of Hematology, Hemostaseology and Coagulation, University Hospital 'Carl Gustav Carus' Dresden, Technical University, Fetscherstrasse 74, D-01307 Dresden, Germany.
Pokaż więcej
Źródło :
Thrombosis research [Thromb Res] 2020 Jul; Vol. 191, pp. 50-55. Date of Electronic Publication: 2020 Apr 25.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Anticoagulants*/pharmacology
Anticoagulants*/therapeutic use
Atrial Fibrillation*/drug therapy
Factor Xa Inhibitors*/pharmacology
Factor Xa Inhibitors*/therapeutic use
Transplant Recipients*
Administration, Oral ; Blood Coagulation/drug effects ; Factor Xa/therapeutic use ; Humans ; Registries
Raport
Tytuł :
Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial.
Autorzy :
Connors JM; Brigham and Women's Hospital, Boston, Massachusetts.
Brooks MM; University of Pittsburgh, Pittsburgh, Pennsylvania.
Sciurba FC; University of Pittsburgh, Pittsburgh, Pennsylvania.
Krishnan JA; University of Illinois Chicago.
Bledsoe JR; Intermountain Healthcare, Murray, Utah.
Kindzelski A; National Heart, Lung, and Blood Institute, Bethesda, Maryland.
Baucom AL; University of Pittsburgh, Pittsburgh, Pennsylvania.
Kirwan BA; SOCAR Research SA, Nyon, Switzerland.
Eng H; University of Pittsburgh, Pittsburgh, Pennsylvania.
Martin D; University of Pittsburgh, Pittsburgh, Pennsylvania.
Zaharris E; Brigham and Women's Hospital, Boston, Massachusetts.
Everett B; Brigham and Women's Hospital, Boston, Massachusetts.
Castro L; University of Illinois Chicago.
Shapiro NL; University of Illinois Chicago.
Lin JY; University of Illinois Chicago.
Hou PC; Brigham and Women's Hospital, Boston, Massachusetts.
Pepine CJ; University of Florida, Gainesville.
Handberg E; University of Florida, Gainesville.
Haight DO; University of South Florida, Lakeland Regional Health, Lakeland.
Wilson JW; Tampa General Hospital, Tampa, Florida.
Majercik S; Intermountain Healthcare, Murray, Utah.
Fu Z; University of Pittsburgh, Pittsburgh, Pennsylvania.
Zhong Y; University of Pittsburgh, Pittsburgh, Pennsylvania.
Venugopal V; University of Pittsburgh, Pittsburgh, Pennsylvania.
Beach S; University of Pittsburgh, Pittsburgh, Pennsylvania.
Wisniewski S; University of Pittsburgh, Pittsburgh, Pennsylvania.
Ridker PM; Brigham and Women's Hospital, Boston, Massachusetts.
Pokaż więcej
Corporate Authors :
ACTIV-4B Investigators
Źródło :
JAMA [JAMA] 2021 Nov 02; Vol. 326 (17), pp. 1703-1712.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
MeSH Terms :
Aspirin/*therapeutic use
COVID-19/*drug therapy
Factor Xa Inhibitors/*therapeutic use
Platelet Aggregation Inhibitors/*therapeutic use
Pyrazoles/*therapeutic use
Pyridones/*therapeutic use
Thrombosis/*prevention & control
Adult ; Aspirin/adverse effects ; COVID-19/complications ; Dose-Response Relationship, Drug ; Double-Blind Method ; Early Termination of Clinical Trials ; Factor Xa Inhibitors/administration & dosage ; Factor Xa Inhibitors/adverse effects ; Female ; Hemorrhage/chemically induced ; Hospitalization ; Humans ; Male ; Middle Aged ; Platelet Aggregation Inhibitors/adverse effects ; Pyrazoles/administration & dosage ; Pyrazoles/adverse effects ; Pyridones/administration & dosage ; Pyridones/adverse effects
Czasopismo naukowe
Tytuł :
Direct oral anticoagulants versus warfarin for the treatment of left ventricular thrombosis.
Autorzy :
Mihm AE; Department of Pharmacy, Atrium Health, Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC, 27157, USA. .
Hicklin HE; Department of Internal Medicine, Atrium Health, Wake Forest School of Medicine, Winston Salem, NC, 27157, USA.
Cunha AL; Department of Pharmacy, Atrium Health, Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC, 27157, USA.; Fred Wilson School of Pharmacy, High Point University, High Point, NC, 27268, USA.
Nisly SA; Department of Pharmacy, Atrium Health, Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC, 27157, USA.; School of Pharmacy, Wingate University, Wingate, NC, 28174, USA.
Davis KA; United Therapeutics Corporation, Durham, NC, 27709, USA.
Pokaż więcej
Źródło :
Internal and emergency medicine [Intern Emerg Med] 2021 Nov; Vol. 16 (8), pp. 2313-2317. Date of Electronic Publication: 2021 Jun 24.
Typ publikacji :
Letter
MeSH Terms :
Factor Xa Inhibitors/*standards
Thrombosis/*drug therapy
Warfarin/*standards
Aged ; Aged, 80 and over ; Anticoagulants/administration & dosage ; Anticoagulants/pharmacology ; Anticoagulants/standards ; Cohort Studies ; Factor Xa Inhibitors/administration & dosage ; Factor Xa Inhibitors/pharmacology ; Female ; Heart Ventricles/drug effects ; Heart Ventricles/physiopathology ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Thrombosis/physiopathology ; Treatment Outcome ; Warfarin/administration & dosage ; Warfarin/pharmacology
Opinia redakcyjna
Tytuł :
The dual FXa/thrombin inhibitor SATI prevents fibrin and platelet deposition in hypercoagulant rats.
Autorzy :
López M; Löwen Apotheke, Friedrichstr. 11-13, 35392 Giessen, Germany; Centro de Biofisica y Bioquimica, Instituto Venezolano de Investigaciones Cientificas, 1020ª Caracas, Venezuela.
Heitmeier S; Research and Development Department, Bayer AG, 42096 Wuppertal, Germany.
Laux V; Research and Development Department, Bayer AG, 42096 Wuppertal, Germany.
Nowak G; Friedrich Schiller University Jena, University Hospital Jena, 07747 Jena, Germany. Electronic address: .
Pokaż więcej
Źródło :
Thrombosis research [Thromb Res] 2020 Sep; Vol. 193, pp. 15-21. Date of Electronic Publication: 2020 May 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Factor Xa Inhibitors*
Thrombin/*antagonists & inhibitors
Animals ; Blood Platelets/metabolism ; Factor Xa/pharmacology ; Fibrin/metabolism ; Microcirculation ; Rats ; Tissue Distribution
Czasopismo naukowe
Tytuł :
Anti-factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors.
Autorzy :
Stuart M; Special Coagulation Laboratory, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Johnson L; Special Coagulation Laboratory, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Hanigan S; College of Pharmacy, University of Michigan Medical School, Ann Arbor, MI, USA.
Pipe SW; Special Coagulation Laboratory, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA.
Li SH; Special Coagulation Laboratory, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Pokaż więcej
Źródło :
Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2020 Jul; Vol. 18 (7), pp. 1653-1660. Date of Electronic Publication: 2020 May 04.
Typ publikacji :
Journal Article
MeSH Terms :
Factor Xa*
Heparin*
Anticoagulants ; Blood Coagulation Tests ; Factor Xa Inhibitors ; Humans ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial.
Autorzy :
Ramacciotti E; Science Valley Research Institute, Santo André, São Paulo, Brazil; Hospital e Maternidade Christóvão da Gama, Grupo Leforte, Santo André, São Paulo, Brazil. Electronic address: .
Agati LB; Science Valley Research Institute, Santo André, São Paulo, Brazil.
Calderaro D; Interdisciplinary Medicine in Cardiology Unit Heart Institute (InCor)- University of São Paulo Medical School, São Paulo, Brazil.
Volpiani GG; Science Valley Research Institute, Santo André, São Paulo, Brazil; Hospital e Maternidade Christóvão da Gama, Grupo Leforte, Santo André, São Paulo, Brazil.
de Oliveira CCC; Science Valley Research Institute, Santo André, São Paulo, Brazil; Hospital e Maternidade Christóvão da Gama, Grupo Leforte, Santo André, São Paulo, Brazil.
Aguiar VCR; Science Valley Research Institute, Santo André, São Paulo, Brazil; Hospital e Maternidade Christóvão da Gama, Grupo Leforte, Santo André, São Paulo, Brazil.
Rodrigues E; Science Valley Research Institute, Santo André, São Paulo, Brazil.
Sobreira ML; Universidade Estadual Paulista (UNESP), Botucatu, Brazil.
Joviliano EE; Hospital das Clínicas de Ribeirão Preto, São Paulo University Medical School (USP), Ribeirão Preto, São Paulo, Brazil.
Dusilek C; Hospital do Rocio, Campo Largo, Paraná, Brazil.
Itinose K; Hospital do Rocio, Campo Largo, Paraná, Brazil.
Dedivitis RA; Irmandade da Santa Casa da Misericórdia de Santos, São Paulo, Brazil.
Cortina AS; Irmandade da Santa Casa da Misericórdia de Santos, São Paulo, Brazil.
Sanches SMV; Hospital Ana Neri, Salvador, Bahia, Brazil.
de Moraes NF; Hospital Municipal de Barueri, São Paulo, Brazil.
Tierno PFGMM; Hospital Municipal de Barueri, São Paulo, Brazil.
de Oliveira ALML; São Paulo State Public Women's Health Reference Center, São Paulo, Brazil.
Tachibana A; Hospital Israelita Albert Einstein, São Paulo, S.P., Brazil.
Chate RC; Hospital Israelita Albert Einstein, São Paulo, S.P., Brazil.
Santos MVB; Heart Institute (InCor)- University of São Paulo Medical School, São Paulo, Brazil.
Cavalcante BBM; Institute of Teaching and Research Hapvida, Fortaleza, CE, Brazil.
Moreira RCR; Hospital Nossa Senhora das Graças, Curitiba, Brazil.
Chiann C; Department of Statistics, Institute of Mathematics and Statistics, University of Sao Paulo, São Paulo, Brazil.
Tafur A; Northshore University Health System, Chicago, IL.
Spyropoulos AC; Zucker School of Medicine at Hofstra/Northwell and the Feinstein Institutes for Medical Research, Manhasset, NY.
Lopes RD; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Pokaż więcej
Źródło :
American heart journal [Am Heart J] 2021 Dec; Vol. 242, pp. 115-122. Date of Electronic Publication: 2021 Sep 01.
Typ publikacji :
Clinical Trial Protocol; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
COVID-19/*complications
Factor Xa Inhibitors/*administration & dosage
Rivaroxaban/*administration & dosage
Thrombosis/*prevention & control
Adult ; Brazil ; Drug Administration Schedule ; Factor Xa Inhibitors/adverse effects ; Female ; Hemorrhage/chemically induced ; Humans ; Male ; Prospective Studies ; Pulmonary Embolism/etiology ; Pulmonary Embolism/prevention & control ; Rivaroxaban/adverse effects ; Thromboembolism/etiology ; Thromboembolism/prevention & control ; Thrombosis/etiology ; Venous Thrombosis/etiology ; Venous Thrombosis/prevention & control
Czasopismo naukowe
Tytuł :
Efficacy and safety of DOACs in patients with peripheral arterial disease: A systematic review and meta-analysis.
Autorzy :
Zhang YS; Department of Vascular Surgery, 56709Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China.
Chen JH; Department of Vascular Surgery, 56709Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China.
Mei T; Department of Vascular Surgery, 56709Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China.
Li S; Department of Vascular Surgery, 56709Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China.
Lu YM; Department of Vascular Surgery, 56709Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China.
Pokaż więcej
Źródło :
Vascular [Vascular] 2021 Dec; Vol. 29 (6), pp. 846-855. Date of Electronic Publication: 2021 Jan 27.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Blood Coagulation/*drug effects
Factor Xa Inhibitors/*therapeutic use
Peripheral Arterial Disease/*drug therapy
Aged ; Factor Xa Inhibitors/adverse effects ; Female ; Hemorrhage/chemically induced ; Humans ; Male ; Middle Aged ; Peripheral Arterial Disease/blood ; Peripheral Arterial Disease/diagnosis ; Peripheral Arterial Disease/mortality ; Risk Assessment ; Risk Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic.
Autorzy :
Curtis HJ; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
MacKenna B; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Walker AJ; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Croker R; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Mehrkar A; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Morton C; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Bacon S; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Hickman G; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Inglesby P; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Bates C; TPP, Leeds, UK.
Evans D; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Ward T; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Cockburn J; TPP, Leeds, UK.
Davy S; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Bhaskaran K; Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Schultze A; Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Rentsch CT; Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Williamson E; Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK.
Hulme W; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Tomlinson L; Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Mathur R; Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Drysdale H; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Eggo RM; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Wong AY; Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Forbes H; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Parry J; TPP, Leeds, UK.
Hester F; TPP, Leeds, UK.
Harper S; TPP, Leeds, UK.
Douglas I; Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Smeeth L; Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Goldacre B; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK .
Pokaż więcej
Corporate Authors :
OpenSAFELY Collaborative
Źródło :
Open heart [Open Heart] 2021 Nov; Vol. 8 (2).
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
COVID-19*
Anticoagulants/*administration & dosage
Blood Coagulation/*drug effects
Drug Substitution/*standards
Factor Xa Inhibitors/*administration & dosage
Practice Guidelines as Topic/*standards
Practice Patterns, Physicians'/*standards
State Medicine/*standards
Warfarin/*administration & dosage
Aged ; Anticoagulants/adverse effects ; Blood Coagulation Tests ; Drug Monitoring ; Drug Prescriptions ; Drug Substitution/adverse effects ; Drug Utilization/standards ; England ; Factor Xa Inhibitors/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Patient Safety ; Primary Health Care/standards ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Warfarin/adverse effects
Czasopismo naukowe
Tytuł :
Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis.
Autorzy :
Mokadem ME; Cardiology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Hassan A; Clinical Oncology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Algaby AZ; Vascular Surgery Department, Faculty of medicine, Beni-Suef University, Beni-Suef, Egypt.
Pokaż więcej
Źródło :
Vascular [Vascular] 2021 Oct; Vol. 29 (5), pp. 745-750. Date of Electronic Publication: 2020 Nov 05.
Typ publikacji :
Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms :
Anticoagulants/*administration & dosage
Enoxaparin/*administration & dosage
Factor Xa Inhibitors/*administration & dosage
Neoplasms/*drug therapy
Pyrazoles/*administration & dosage
Pyridones/*administration & dosage
Venous Thrombosis/*drug therapy
Administration, Oral ; Aged ; Anticoagulants/adverse effects ; Egypt ; Enoxaparin/adverse effects ; Factor Xa Inhibitors/adverse effects ; Female ; Hemorrhage/chemically induced ; Humans ; Injections, Subcutaneous ; Male ; Middle Aged ; Neoplasms/complications ; Neoplasms/diagnosis ; Pyrazoles/adverse effects ; Pyridones/adverse effects ; Time Factors ; Treatment Outcome ; Venous Thrombosis/diagnostic imaging ; Venous Thrombosis/etiology
Czasopismo naukowe
Tytuł :
Efficacy and Safety of Rivaroxaban Therapy for Patients With Peripheral Artery Disease: A Systematic Review and Meta-Analysis.
Autorzy :
Hao Y; Department of Vascular Surgery, Shouguang People's Hospital, Weifang, Shandong, China.
Han W; Department of Vascular Surgery, Shouguang People's Hospital, Weifang, Shandong, China.
Mou D; Department of Vascular Surgery, Shouguang People's Hospital, Weifang, Shandong, China.
Wang J; Department of Vascular Surgery, Shouguang People's Hospital, Weifang, Shandong, China.
Pokaż więcej
Źródło :
Vascular and endovascular surgery [Vasc Endovascular Surg] 2021 Oct; Vol. 55 (7), pp. 712-720. Date of Electronic Publication: 2021 May 25.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Factor Xa Inhibitors/*therapeutic use
Peripheral Arterial Disease/*drug therapy
Rivaroxaban/*therapeutic use
Aged ; Amputation ; Disease Progression ; Factor Xa Inhibitors/adverse effects ; Female ; Hemorrhage/chemically induced ; Humans ; Limb Salvage ; Male ; Peripheral Arterial Disease/diagnosis ; Randomized Controlled Trials as Topic ; Risk Assessment ; Risk Factors ; Rivaroxaban/adverse effects ; Time Factors ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies